Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer

Fig. 5

FFAR4 activation via endogenous or synthetic ligands confers tamoxifen resistance in HRPBC. a Immunoblot analyses of FFAR4 expression in human HRPBC cell lines MCF-7 and T-47D. b Cell viability of MCF-7 and T-47D cells treated with different concentrations of 4OHT (0, 0.1, 1, 2, 4, 8 and 16 μM). Cell viability of MCF-7 (c) and T-47D (d) cells treated with 4OHT (8 μM) and different concentrations (0, 5, 10, 50 and 100 μM) of endogenous FFAR4 ligands SA, DGLA and DHA. e Cell viability of MCF-7 and T-47D cells treated with 4OHT (8 μM) and different concentrations (0, 1, 5, 10 and 50 μM) of synthetic FFAR4 ligand TUG891. f Cell viability of MCF-7 and T-47D cells treated with 4OHT (8 μM) and TUG891 (10 μM) with or without AH7614 (10 μM) preincubation (30 min). Cells were seeded in 96-well plate, allowed to grow for 48 h before treatments with indicated reagents for 48 h. Cell viabilities were then measured using WST-1 substrates. Data were representative of three independent experiments. 4OHT, 4-hydroxytamoxifen. Error bars represent standard deviation of cell viability (%). *** P <  0.001

Back to article page